Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis
Oxidative stress is a driving factor in the pathophysiology of chronic obstructive pulmonary disease (COPD). While paraoxonase 1 (PON1) is an antioxidant enzyme and a potential biomarker of this disease, data regarding the status of PON-1 in COPD are inconclusive. In this regard, to shed light on th...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3921/10/12/1891 |
| _version_ | 1797506857527410688 |
|---|---|
| author | Jun Watanabe Kazuhiko Kotani Alejandro Gugliucci |
| author_facet | Jun Watanabe Kazuhiko Kotani Alejandro Gugliucci |
| author_sort | Jun Watanabe |
| collection | DOAJ |
| description | Oxidative stress is a driving factor in the pathophysiology of chronic obstructive pulmonary disease (COPD). While paraoxonase 1 (PON1) is an antioxidant enzyme and a potential biomarker of this disease, data regarding the status of PON-1 in COPD are inconclusive. In this regard, to shed light on this issue, we performed a meta-analysis of data on PON1 activity in COPD. Electronic databases (MEDLINE, Embase and CENTRAL) were searched for available studies on PON1 activity in patients with stable COPD published before October 2021. A meta-analysis was performed using random-effects models. Twelve studies (12 studies on paraoxonase and three on arylesterase) were identified. Patients with COPD had lower levels of paraoxonase activity (standard mean difference [SMD] −0.77, 95% confidence interval [CI] −1.35 to −0.18) and arylesterase activity (SMD −1.15, 95% CI −1.95 to −0.36) in comparison to healthy controls. In subgroup analyses, paraoxonase activity was lower in patients of studies as consisted of mainly non-severe COPD (SMD −1.42, 95% CI −2.04 to −0.79) and, by contrast, slightly higher in patients of studies including severe COPD (SMD 0.33, 95% CI 0.02 to 0.64) in comparison to healthy controls. Arylesterase activity showed a similar trend. Overall, PON1 activity was lower in patients with COPD, suggesting that PON1-related antioxidant defense is impaired in COPD. Future studies are warranted. |
| first_indexed | 2024-03-10T04:38:27Z |
| format | Article |
| id | doaj.art-4275519deda548b68df58d632bf214f0 |
| institution | Directory Open Access Journal |
| issn | 2076-3921 |
| language | English |
| last_indexed | 2024-03-10T04:38:27Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antioxidants |
| spelling | doaj.art-4275519deda548b68df58d632bf214f02023-11-23T03:32:30ZengMDPI AGAntioxidants2076-39212021-11-011012189110.3390/antiox10121891Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-AnalysisJun Watanabe0Kazuhiko Kotani1Alejandro Gugliucci2Division of Community and Family Medicine, Jichi Medical University, Shimotsuke 329-0498, JapanDivision of Community and Family Medicine, Jichi Medical University, Shimotsuke 329-0498, JapanGlycation, Oxidation and Disease Laboratory, Touro University-California, Vallejo, CA 94592, USAOxidative stress is a driving factor in the pathophysiology of chronic obstructive pulmonary disease (COPD). While paraoxonase 1 (PON1) is an antioxidant enzyme and a potential biomarker of this disease, data regarding the status of PON-1 in COPD are inconclusive. In this regard, to shed light on this issue, we performed a meta-analysis of data on PON1 activity in COPD. Electronic databases (MEDLINE, Embase and CENTRAL) were searched for available studies on PON1 activity in patients with stable COPD published before October 2021. A meta-analysis was performed using random-effects models. Twelve studies (12 studies on paraoxonase and three on arylesterase) were identified. Patients with COPD had lower levels of paraoxonase activity (standard mean difference [SMD] −0.77, 95% confidence interval [CI] −1.35 to −0.18) and arylesterase activity (SMD −1.15, 95% CI −1.95 to −0.36) in comparison to healthy controls. In subgroup analyses, paraoxonase activity was lower in patients of studies as consisted of mainly non-severe COPD (SMD −1.42, 95% CI −2.04 to −0.79) and, by contrast, slightly higher in patients of studies including severe COPD (SMD 0.33, 95% CI 0.02 to 0.64) in comparison to healthy controls. Arylesterase activity showed a similar trend. Overall, PON1 activity was lower in patients with COPD, suggesting that PON1-related antioxidant defense is impaired in COPD. Future studies are warranted.https://www.mdpi.com/2076-3921/10/12/1891antioxidantarylesterasechronic obstructive lung diseasereactive oxygen speciesparaoxonase |
| spellingShingle | Jun Watanabe Kazuhiko Kotani Alejandro Gugliucci Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis Antioxidants antioxidant arylesterase chronic obstructive lung disease reactive oxygen species paraoxonase |
| title | Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis |
| title_full | Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis |
| title_fullStr | Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis |
| title_full_unstemmed | Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis |
| title_short | Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis |
| title_sort | paraoxonase 1 and chronic obstructive pulmonary disease a meta analysis |
| topic | antioxidant arylesterase chronic obstructive lung disease reactive oxygen species paraoxonase |
| url | https://www.mdpi.com/2076-3921/10/12/1891 |
| work_keys_str_mv | AT junwatanabe paraoxonase1andchronicobstructivepulmonarydiseaseametaanalysis AT kazuhikokotani paraoxonase1andchronicobstructivepulmonarydiseaseametaanalysis AT alejandrogugliucci paraoxonase1andchronicobstructivepulmonarydiseaseametaanalysis |